Controlled clinical trials have shown tesamorelin, a growth hormone–releasing hormone analog, can significantly cut visceral fat while sparing subcutaneous fat. The effect has been replicated in ...

Tesamorelin, a synthetic peptide analog of growth hormone-releasing hormone (GHRH), has recently garnered attention for its unique biochemical properties and intriguing impact on various physiological ...

MELBOURNE, Australia -- HIV-infected patients treated with a growth hormone releasing hormone analog achieved modest reductions in abdominal and liver fat, researchers said. The results were also ...

Please provide your email address to receive an email when new articles are posted on . “We have phenomenally successfully direct-acting antiretrovirals for HIV that have saved the lives of people and ...

November 12, 2010 — The US Food and Drug Administration (FDA) has approved tesamorelin acetate injection (Egrifta; Theratechnologies, Inc, and marketed by EMD Serono) as the first and only treatment ...

Multiple randomized controlled trials have shown that tesamorelin, a growth hormone–releasing hormone analog, can selectively reduce visceral fat by about 15% over 26 weeks in HIV patients, with no ...

Montréal, Canada - November 11, 2010 - Theratechnologies (TSX: TH) announced today that the U.S. Food and Drug Administration ("FDA") has approved EGRIFTATM (tesamorelin for injection) as the first ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Tesamorelin is increasingly used as a laboratory tool when investigators need a GHRH analog reference material that can be applied consistently across receptor pharmacology assays, secretome profiling ...

Review the side-effects of Tesamorelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...